Memantina Pharmakern

Memantine Hydrochloride, the active ingredient in Memantina Pharmakern, is an NMDA receptor antagonist presented as an oral formulation for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to reduce excitotoxic neuronal damage.

GNH USA supplies Memantina Pharmakern as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution to meet the needs of healthcare providers effectively.

Memantine Hydrochloride acts on the glutamatergic system and is used in the management of Alzheimer’s disease.

Alzheimer’s disease (moderate to severe): improves cognition and daily functioning. Cognitive decline in Alzheimer’s: helps slow the rate of deterioration. Behavioral symptoms of Alzheimer’s: may reduce agitation and improve patient cooperation.

Memantine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: transient disorientation. - Insomnia: difficulty initiating or maintaining sleep. - Hypertension: elevated blood pressure readings.

Serious or Rare Side Effects: - Seizures: convulsive episodes requiring medical attention. - Cardiac arrhythmia: irregular heart rhythm. - Severe skin rash: including Stevens‑Johnson syndrome. - Hepatic injury: elevated liver enzymes or hepatitis. - Suicidal thoughts: emergence of depressive ideation. - Neuroleptic malignant‑like syndrome: rare but life‑threatening reaction.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential risks.

Renal impairment: dose may need adjustment based on creatinine clearance. History of seizures: monitor closely for increased seizure activity. Cardiovascular disease: use with caution in patients with arrhythmias or hypertension. Concurrent NMDA antagonists: avoid combination to prevent additive neurotoxicity. Pregnancy and lactation: safety not established; weigh benefits against potential risks. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Memantine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Ketamine: additive NMDA antagonism leading to excessive CNS depression. - Other NMDA antagonists: heightened risk of adverse neurologic effects.

Moderate Interactions (Monitor Closely): - Anticholinergics: may diminish memantine’s cognitive benefits. - Diuretics: can raise plasma concentrations of memantine. - CNS depressants (e.g., benzodiazepines): may enhance dizziness and sedation.